We are a pharmaceutical company that has been wanting to do things differently for years. We go beyond compliance and are guided by ethics, integrity and responsibility.
Business
We use business to fight for social justice
We are a vertically integrated pharmaceutical company that combines research and development, manufacturing of active pharmaceutical ingredients, production and commercialization to help scientific innovation reach the people who need it most. Our products are present in more than 100 countries and we have a team of around 1,700 people.
In line with our purpose, we have intensified our focus on rare diseases and focus our efforts on pulmonary vascular and interstitial pulmonary diseases, as well as rare neurological diseases. Because we believe that no patient should be left behind simply because their disease is rare, complex, or difficult to treat.
The Way We Do Business
Our focus
At Ferrer, we work for a fairer society through transformative medicines that improve people's lives. We have focused our activity on serious diseases, of low prevalence and with few or no therapeutic options, where we believe we can make a difference.
Science
Our R+D strategy focuses on therapeutic areas with a high social and health impact, addressing rare diseases with progressive progression and serious prognosis through innovative and sustainable solutions. In doing so, we strengthen our alignment with European public health priorities and respond to the need to improve the lives of patients, family members, carers and healthcare systems.
Related news
-
Ferrer and Prilenia Announce Start of PRECISE-HD Confirmatory Clinical Trial of Pridopidine in Huntington's Disease
5 -
First participant in Europe in the Phase 3 clinical trial "PREVAiLS" with pridopidine, in ALS
5 -
IMPAHCT celebrates its eighth edition by reinforcing the comprehensive approach to rare lung diseases
5 -
Ferrer and Prilenia Announce Inclusion of First Participant in Phase 3 Clinical Trial "PREVAiLS" with Pridopidine, in ALS
5
